91AV

Advance Best- or First- in Class Candidates, Demonstrate Differentiation and Validate Technologies Within these hyper-competitive landscapes, differentiating assets targeting proven targets, balancing efficacy with worsening toxicity, or securing minimum evidence to validate a platform are all avenues for biotech to pursue to align with pharma and investor expectations.

For biotech across ADCs, TCEs, BsAbs, TPD, and in vivo CAR-T, competing to align earlier clinical proof-of-concept data with pharma expectations, the Oncology and Immunology Innovation Partnering and Licensing Summit shares modality-specific decision-making, longer, and less competitive networking, and insights into how peers are pitching.

Ensuring relevance, favorable pharma-to-biotech ratios, and synergy across attendee interests, this high-impact forum is strategically timed between BIO and JPM as a targeted touch point.

Who Attends This Differentiated Business Development Initiative?

- Large Pharma: Heads of Business Development, Search and Evaluation, and Asset Scouting for Oncology and Immunology - comparing pipelines and enabling technologies to fuel future innovation. - Innovative Biotech: C-level executives and BD leaders across TPD, ADCS, BsABs, TCEs, and in vivo CAR-Ts - seeking feedback, validation, and an understanding of partnership expectations with pharma and investors. - Investors and Venture Capital: Leaders focused on disruptive investments with a higher risk appetite or looking for more validated, clinical data, looking for an opportunity to engage with peers in a relaxed environment.

Marrying collaboration across shared interests whilst delivering modality-specific depth. Pharma assesses related programs without dilution; biotech gets more efficient, higher-yielding networking.

听

Time: 7:00 AM - 5:00 PM